The American Brain Tumor Association (ABTA), in partnership with the Brain Tumor Funders’ Collaborative (BTFC), is on a mission to revolutionize brain tumor diagnosis and monitoring with cutting-edge liquid biopsy technology. This groundbreaking approach promises to detect primary brain tumors earlier, offer more precise diagnoses, and enable continuous clinical monitoring. By advancing liquid biopsy methods, the ABTA and BTFC aim to extend patient survival, improve quality of life, and bring hope to patients across all age groups—including pediatric, adolescent, young adult (AYA), and adult populations. They are committed to funding innovative research that will make liquid biopsy a powerful tool in brain tumor care.
